Experimental combo for tough leukemia hits early snag
NCT ID NCT05716009
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a combination of two targeted drugs—tagraxofusp-erzs and gemtuzumab ozogamicin—in 7 patients with acute myeloid leukemia that had come back or not responded to treatment. The goal was to find a safe dose and see if the combination could control the disease. The study was terminated early, so we have limited information on how well it worked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tagraxofusp-erzs (a drug that links interleukin-3 with a diphtheria toxin) combined with gemtuzumab ozogamicin (an antibody-drug conjugate)
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for patients with hard-to-treat acute myeloid leukemia.
What could go wrong
This was a very early (phase 1) trial with only 7 participants, and it was terminated, so results are limited. The combination may cause serious side effects and may not work for most patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21287, United States